

Appendix Table. Adjusted Outcomes with Cost Breakdown and Illness Severity Stratification

Low Illness Severity

	Clindamycin	Clindamycin + MSSA	Clindamycin + MRSA	p-value
Length of Stay in Days (95% CI)	2.3 (2.3, 2.4)	2.3 (2.3, 2.4)	2.3 (2.3, 2.4)	0.994
Mean Cost in US Dollars (95% CI)	4569.8 (3962.2, 5270.6)	4819.3 (4164, 5577.8)	5063.2 (4379.9, 5853.1)	0.001
CLINICAL	210.1 (137.6, 320.7)	232.2 (149, 362)	249.2 (160.9, 385.9)	0.351
PHARMACY	246.9 (176.1, 346.4)	309.6 (218.7, 438.2)	387.6 (274.7, 546.9)	<.001
IMAGING	175.2 (81.1, 378.6)	169.1 (77.4, 369.4)	149.2 (63.4, 351.1)	0.934
LAB	437 (325.1, 587.5)	475.6 (348.4, 649.1)	609.8 (449.3, 827.6)	<.001
SUPPLY	86.5 (46.1, 162.2)	67.4 (35.1, 129.4)	115.5 (60.3, 221.1)	0.011
OTHER	3234.2 (2777.9, 3765.3)	3289.7 (2818.4, 3839.8)	3345.5 (2868.7, 3901.6)	0.388
Treatment Failure, % (95% CI) ¹	0.8 (0, 4.7)	0.2 (0, 4.3)	1 (0, 5)	0.794

Moderate/High Illness Severity

	Clindamycin	Clindamycin + MSSA	Clindamycin + MRSA	p-value
Length of Stay in Days (95% CI)	2.3 (2.3, 2.4)	2.4 (2.3, 2.5)	2.3 (2.3, 2.4)	0.169
Mean Cost in US Dollars (95% CI)	5059.8 (4292.5, 5964.2)	5629.1 (4744.2, 6679.1)	5565.7 (4705.2, 6583.6)	0.034
CLINICAL	241.8 (131, 446.3)	265.7 (139.4, 506.5)	266 (145.3, 486.9)	0.881
PHARMACY	241.3 (168.5, 345.8)	366 (251.4, 532.8)	417.4 (288.9, 603)	<.001
IMAGING	217.8 (107.1, 442.9)	148.6 (72, 306.4)	110.8 (49.1, 250.2)	0.348
LAB	519.3 (388.7, 693.7)	556.3 (407.1, 760.1)	668.5 (494.8, 903.2)	0.114
SUPPLY	60.1 (29.7, 121.3)	77.2 (37.7, 158.2)	84 (41.3, 171.1)	0.360
OTHER	3466.2 (2916.6, 4119.4)	3695.4 (3093.1, 4414.9)	3500.7 (2937.1, 4172.4)	0.284
Treatment Failure, % (95% CI) ¹	0 (0, 3.5)	0 (0, 3.2)	2.4 (0, 6.2)	0.138

Abbreviations: CI: confidence interval; MSSA: methicillin sensitive *Staphylococcus aureus*; MRSA: methicillin resistant *Staphylococcus aureus*

¹Defined as same-cause 14-day readmission or emergency department revisit